文献速递泌尿生殖与妇科肿瘤放疗姑息放疗与转移瘤

接受放射治疗的人类免疫缺陷病毒/艾滋病患者前列腺癌结局:一项系统评价

Prostate Cancer Outcomes in Patients Living With HIV/AIDS Treated With Radiation Therapy: A Systematic Review.
PubMed 文献 · Adv Radiat Oncol · 2022-09-21

该系统评价共纳入9项研究、187例感染HIV的前列腺癌患者,多数接受外照射放疗(59%),4年或5年生化失败无复发生存率为87%至97%,2项研究报告5年癌症特异性生存率为84%至97%,仅2例观察到3级毒性。作者认为根治性放疗在PLWHA中有效且耐受良好,但放疗对CD4计数和病毒载量的影响证据不一,需进一步研究。

要点

  • 9项研究187例HIV感染前列腺癌患者,59%接受外照射放疗、20.5%接受近距离治疗。
  • 3项研究报告4年或5年生化失败无复发生存率为87%至97%。
  • 2项研究报告5年癌症特异性生存率为84%至97%,仅2例出现3级毒性。

核心结论

  • 放疗在PLWHA中有效且耐受良好,生化控制、临床结局和死亡率与一般人群相当,放射毒性报告轻微。
  • 关于放疗对CD4计数和病毒载量影响的证据不一,需进一步研究以更好理解这一关系。
  • 这些发现支持在PLWHA合并前列腺癌患者中使用根治性放疗。

研究设计与样本

  • 系统评价,于2021年9月在PubMed、Cochrane Library和Scopus数据库检索,采用PRISMA标准。
  • 纳入报告接受根治性放疗的PLWHA前列腺癌结局的文章,共纳入9项研究、187例HIV感染的前列腺癌患者。

主要发现

  • HIV感染至前列腺癌诊断的持续时间为8.5至18.6年,诊断时69%至100%的患者正在接受高效抗逆转录病毒治疗。
  • 患者前列腺特异性抗原水平范围为8至82 ng/mL。
  • 多数患者(59%)接受外照射放疗,其次为近距离治疗(20.5%)。
  • 3项研究报告4年或5年生化失败无复发生存率在87%至97%之间,2项研究报告5年癌症特异性生存率为84%至97%。
  • 采用常见不良事件评价标准,3项研究报告毒性,仅2例观察到3级毒性。

关键数值与推荐

  • 4年或5年生化失败无复发生存率为87%至97%(3项研究)。
  • 5年癌症特异性生存率为84%至97%(2项研究)。
  • 3级毒性仅见于2例患者(3项研究报告毒性)。

临床怎么用

  • 作者结论认为这些发现支持在PLWHA合并前列腺癌患者中使用根治性放疗。
  • 作者指出关于放疗对CD4计数和病毒载量影响的证据不一,需进一步研究。

局限性

  • 关于放疗对CD4计数和病毒载量影响的证据不一,需进一步研究以更好理解这一关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: A consensus has not been reached regarding the treatment and outcomes of prostate cancer (PCa) in people living with HIV/AIDS (PLWHA). This systematic review aims to summarize the evidence on the management of PCa with radiation therapy (RT) in PLWHA diagnosed with PCa. METHODS AND MATERIALS: Searches were conducted in the PubMed, Cochrane Library, and Scopus databases during September 2021 using Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) criteria. Articles reporting on outcomes of PLWHA treated for PCa with definitive RT were sought for inclusion. RESULTS: A total of 9 studies with 187 patients with HIV who received diagnoses of PCa met inclusion criteria. The duration of HIV infection to PCa diagnosis ranged from 8.5 to 18.6 years with 69% to 100% of patients on highly active antiretroviral therapy at the time of diagnosis. Patients' prostate-specific antigen levels ranged from 8 to 82 ng/mL. The majority of patients (59%) were treated with external beam RT, followed by brachytherapy (20.5%). The 4- or 5-year biochemical failure-free rate was reported to be between 87% and 97% in 3 studies, and 2 studies reported an 84% to 97% 5-year cancer-specific survival. Using Common Terminology Criteria for Adverse Events criteria, 3 studies reported toxicities and grade 3 toxicity was observed in only 2 patients. CONCLUSIONS: RT is efficacious and well tolerated in PLWHA as supported by the comparable biochemical control, clinical outcome, and mortality to the general population as well as by the mild reports of radiotoxicity. There is mixed evidence regarding the effect of RT on CD4 count and viral load, and further studies are needed to better understand this relationship. These findings support the use of definitive RT in PLWHA with PCa.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Vaziri T, Rao YJ, Whalen M, et al. Prostate Cancer Outcomes in Patients Living With HIV/AIDS Treated With Radiation Therapy: A Systematic Review. Adv Radiat Oncol. 2022. PMID: 36299566. doi:10.1016/j.adro.2022.101074

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。